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The documentation of psychopathology is core to the clinical practice of the psychi-
atrist and clinical psychologist. However, both in initial as well as further training and 
specialization in their fields, this particular aspect of their work receives scanty attention 
only. Yet, for the past 50 years, the Association for Methodology and Documentation 
in Psychiatry (AMDP) System has been in existence and available as a tool to serve 
precisely the purpose of offering a systematic introduction to the terminology and 
documentation of psychopathology. The motivation for its development was based on the 
need for an assessment procedure for the reliable documentation of the effectiveness of 
newly developed psychopharmacological substances. Subsequently, the AMDP-System  
began to be applied in the context of investigations into a number of methodological 
issues in psychiatry (e.g., the frequency and specificity of particular symptoms, the 
comparison of rating scales). The System then became increasingly important also in 
clinical practice and, today, represents the most used instrument for the documentation 
of psychopathology in the German-speaking countries of Europe. This paper intends 
to offer an overview of the AMDP-System, its origins, design, and functionality. After an 
initial account of the history and development of the AMDP-System, the discussion will 
in turn focus on the System’s underlying methodological principles, the transfer of clinical 
skills and competencies in its practical application, and its use in research and clinical 
practice. Finally, potential future areas of development in relation to the AMDP-System 
are explored.
Keywords: Association for Methodology and Documentation in Psychiatry system, psychopathology, 
observer rating scale, assessment, AMDP-System, documentation
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iNTRODUCTiON
Psychopathology has enjoyed a long tradition in psychiatric 
literature [e.g., Kraepelin, Bleuler, Jaspers, Schneider; cf. Ref. 
(1, 2)]. Semple et al. (3), p. 80, describe this area of specializa-
tion in the following terms: “Psychopathology is the study of 
abnormalities in mental states and is one of the core sciences 
in clinical psychiatry. Descriptive psychopathology is one 
method for describing the subjective experience and behavior 
of patients and is the basis for our current clinical descriptions 
of mental disorder.” In recent years, interest in the systematic 
discussion of psychopathological questions has waned. One 
possible reason for this may be the introduction of operation-
alized diagnosis by classification systems such as the World 
Health Organization’s ICD-10 (since 1992) and the American 
Psychiatric Association’s DSM-III (1980; current version: 
DSM-5 since 2013). An aspect which remains persistently 
ignored in the context of these classification systems is the fact 
that most of their diagnostic criteria consist of psychopathologi-
cal symptoms, and a firm command of a comprehensive body 
of psychopathological knowledge and expertise is, therefore, an 
essential requirement for establishing a clinical diagnosis based 
on either of these systems.
Descriptions of psychopathological phenomena of patients’ 
experiences and behaviors are found in earliest editions of sys-
tematic textbooks of psychiatry and psychology. The philosopher 
Karl Jaspers, in his general psychopathology (German title: 
Allgemeine Psychopathologie), laid the foundation for psycho-
pathology as a scientific discipline in its own right. Since then, 
psychopathology has featured as the essential basic core subject 
in the study of psychiatry and clinical psychology. The discovery 
and development of psychotropic drugs during the mid-1950s 
prompted a widening of the discussion on psychopathological 
issues. For the first time in the history of psychiatry, new forms of 
therapy were able to effect rapid changes in a patient’s mental state. 
This triggered the need for precise and accurate recording of such 
medication-induced changes in a patient in order to accurately 
and comprehensively track and document a patient’s develop-
ment throughout a given course of treatment. Psychotropic drugs 
opened up entirely new opportunities for differential therapies 
in the treatment of psychopathological disorders. As a result, 
differential diagnosis became an absolute prerequisite for effective 
differential therapy in the field of psychiatry also, as was already the 
case in all other medical disciplines. The first versions of a number 
of rating scales were designed [cf. Association for Methodology 
and Documentation in Psychiatry (AMDP) and CIPS, 1990], 
such as the Present State Examination (PSE) Scale, the Brief 
Psychiatric Rating Scale (BPRS), the Inpatient Multidimensional 
Psychiatric Scale (IMPS), and the Comprehensive Psychiatric 
Rating Scale (CPRS). These developments coincided with the 
creation also of the AMDP-System. While most first-generation 
assessment scales and procedures (e.g., PSE, IMPS, CPRS) have 
since been superseded and are now rarely applied or persist in 
modified form only (BPRS), the AMDP-System continues to 
enjoy widespread acceptance and use in its largely unaltered 
original form, predominantly in the German-speaking countries 
of Europe.
HiSTORY OF THe AMDP-SYSTeM
In 1952, the two French psychiatrists, Delay and Deniker, pub-
lished their clinical findings on the calming, stabilizing effects of 
chlorpromazine [cf. Ref. (4)] and thus initiated the development 
of modern psychotropic substances. This, in turn, laid the founda-
tion for a new scientific discipline: the discipline of psychophar-
macology, which led, inter alia, to Kuhn and Janssen’s respective 
discoveries of the antidepressant effect of imipramine and the 
antipsychotic drug haloperidol [cf. Ref. (5)]. During that time, 
numerous new substances were undergoing clinical trials. While 
the effectiveness of these new substances was clearly observable, 
the objective assessment of such findings was rendered difficult 
in the absence of the scientific instruments necessary for this 
purpose.
In order to counter this problem, two working groups formed 
independently of each other at university clinics in Germany and 
Switzerland. Their common objective was to design and develop 
an instrument that would enable the systematic recording and 
assessment of the effects of new psychotropic drugs on individual 
patients. Subsequent close cooperation between the two groups 
ultimately led to the formation of the AMDP [cf. Ref. (6)]. The 
purpose of the intended instrument was not only to facilitate 
the documentation of medical histories of psychiatric patients 
but also to offer a comprehensive overview of psychopathologi-
cal and somatic symptoms with the specific aim of facilitating 
the exchange of information in relation to psychiatric medical 
histories, assessments, and findings at an international level. The 
resulting instrument has since undergone further improvement 
and development to accommodate findings from widening 
clinical experience as well as from an increasingly large body 
of empirical studies (e.g., a reduction of the number of items 
listed in the overview of psychopathological symptoms from 123 
to 100 and of somatic symptoms from 58 to 40). Since 1979, 
the instrument has been commonly known and referred to as 
the AMDP-System (7). In Germany, besides finding application 
as a research instrument, the AMDP-System soon also began 
to serve as the basis for routine medical reports on admission 
and discharge at several psychiatric university clinics. Training 
seminars are primarily used to improve the quality of the col-
lected data (interrater reliability) in research as well as in clinical 
routine.
In addition to engaging in the creation and development of 
the AMDP-System, the AMDP working group began to organize 
symposia for the purpose of addressing methodological issues 
in psychiatry (e.g., questions concerning the recording and 
assessment of changes observed in patients under treatment), 
developing supplementary modules (e.g., in relation to nega-
tive symptoms), and promoting the translation of the AMDP-
System into different languages. In 1976, Daniel Bobon (Liège) 
established an international secretariat (8). The AMDP Manual 
was translated from its original German version into various 
other languages, including Danish, Japanese, Croatian, Dutch, 
Russian, Greek, and Italian (8). In 1980, an English-speaking 
AMDP working group was established, and the publication of a 
first English edition of the AMDP-System followed 2 years later 
(9). A new, updated English version of the AMDP Manual is 
TABle 1 | Structure of an Association for Methodology and 
Documentation in Psychiatry (AMDP) symptom description: example.
34. Delusional perception (S)
Definition
Abnormal significance/meaning, usually related to one’s self, is attributed to real 
perceptions. This happens without the presence of a rationally or emotionally 
understandable underlying reason. This symptom represents a delusional 
misinterpretation of an accurate perception of an external stimulus.
Explanations and examples
During a walk in the park, a patient notices a dog looking at him and lifting one of 
its front paws. The patient interprets this as a sign of divine revelation.
“Mnestic delusional perceptions,” as particular forms of delusional perception, 
are also documented here: “When I was a kid I had a fork which had this symbol 
of a crown engraved on it. Now I suddenly realise what that was meant to mean 
– I’m clearly of noble descent!”
Instances of mistaken identity are also recorded here as long as the act of 
recognition is of genuine character (i.e., meets the criteria for a delusional 
perception).
Instances of delusional perception reported and recorded prior to the current 
period of assessment are classified as 36. Delusional ideas and documented there
Notes on rating
“Mild” Instances of delusional perception are limited to specific areas of 
experience (one instance of reported delusional perception within the 
current period of assessment).
“Severe” The patient’s entire experience is dominated by delusional perceptions 
(in excess of three different instances of delusional perception reported 
within the current period of assessment).
Symptoms to differentiate from
35. Sudden delusional ideas
36. Delusional ideas
47. Illusions
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due for publication in 20171; also published resp. planned are 
editions in Portuguese, French, and Norwegian. Another clear 
indication of the AMDP working group’s commitment to an 
international focus is also the publication of a further manual 
in collaboration with the CIPS (Collegium Internationale 
Psychiatriae Scalarum) on the application and use of rating 
scales in psychiatry. This manual contains references to the 16 
self-rating and observer-rating scales most commonly applied in 
psychiatric studies and research (along with the AMDP-System, 
these include e.g., the Hamilton Scale (HAMD), the BPRS, the 
Bech-Rafaelsen Mania Scale, and the BRMS; also the Clinical 
Global Impression rating scale, CGI). Each of these scales is 
reproduced in the manual in four languages (English, French, 
Italian, and German).
Since 1988, the AMDP working group has been further 
committed to the training of psychiatrists and psychologists in 
descriptive psychopathology (e.g., by regularly organizing multi-
day training seminars in this field).
The year 2016 saw the publication of the ninth revised 
German edition of the AMDP-System with an additional section 
on optionally applicable new symptoms. For psychopathological 
findings, these are panic attack, acceleration of thinking, ideas 
of reference, disorganized behavior, lack of boundaries, thought 
hearing, impulsive behavior, disturbance of body image, feelings 
of shame, overvalued ideas, and anomic aphasia; for somatic 
findings, they are parasomnia, increased libido, and sexual dis-
turbances. This ninth revised edition of the AMDP-System will 
also form the basis for its new, forthcoming foreign-language 
editions.
MeTHODOlOGiCAl ASPeCTS OF THe 
AMDP-SYSTeM
Since its inception, the AMDP working group has been, as its 
name suggests, extensively concerned with methodological issues 
relating to the documentation and diagnosis in psychiatry. Its 
initial goal, however, was the development of a rating scale with 
particular focus on the following three aspects:
 1. precise definitions of psychopathological terms/symptoms;
 2. clear definitions of assessment criteria for individual psycho-
pathological phenomena;
 3. and the operationalization of assessment procedures for 
individual psychopathological phenomena.
These objectives were born out of the observation that psy-
chopathological terms often tended to be interpreted and applied 
in an inconsistent, imprecise manner. The AMDP Manual, the 
result of a development process covering several years, offers 
clear, precise definitions of 100 psychopathological and 40 
somatic symptoms and of a number of supplementary, optionally 
applicable symptoms for both of these categories (11 symptoms 
and 3 symptoms, respectively). Individual entries for each of the 
1 Broome M, Bottlender R, Rösler M, Stieglitz R-D. The AMDP-System. 
Göttingen: Hogrefe (in press).
symptoms listed in the manual adhere to the same structure, as 
follows:
•	 definition
•	 explanations and examples
•	 notes on rating
•	 symptoms to differentiate from.
Table 1 below contains an extract from the AMDP Manual in 
the form of such an entry. A short, concise definition of the symp-
tom is followed by more in-depth and descriptive details in order 
to lead to a better understanding of the term defined (e.g., likely 
examples of a patient’s verbal utterances). Psychopathological 
phenomena, as far as their presence or absence in a patient is 
concerned, manifest by degree rather than on an all-or-nothing 
basis. Assessment advice given for a particular symptom focuses 
on descriptions of the degrees of severity of “mild” and “severe.” 
Both these levels are intended as threshold levels at which the 
recording of manifestations of a symptom as “mild” or “severe” 
becomes justified. The section on “Symptoms to differentiate 
from” is intended to offer further assistance in determining the 
potential presence or absence of a particular symptom.
A clear definition of a specific symptom, however, does not 
suffice as long as the basis on which to make an assessment remains 
unclear. The following are considered potential sources of data 
on which to base an assessment: the patient, the rater (i.e., the 
examining physician or clinician), and third parties (e.g., care 
staff, family members, and close relatives). These potential 
neologisms 
flight of 
ideas 
depressed 
mood 
lack of 
drive 
verbal 
hallucinations 
inhibited 
thinking 
felt loss of 
vitality 
incoherence 
S SO O 
FiGURe 1 | Data sources for Association for Methodology and 
Documentation in Psychiatry (AMDP) symptoms (S, self; O, other; SO, 
self or other).
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sources each assume varying degrees of significance in con-
nection with the assessment of individual psychopathological 
symptoms. Some psychopathological symptoms can be reliably 
assessed exclusively on the basis of a patient’s personal account 
(e.g., in the case of hallucinations), while other symptoms are 
observable only by the rater or third parties with the patient 
remaining consciously unaware of being afflicted with any form 
of disorder (e.g., a formal disorder of thought such incoherence 
or neologisms). With a third group of symptoms, assessment is 
possible by the patient as well as third parties (e.g., lack of drive). 
In view of these differences, each symptom has been allocated one 
of the following data source categories:
•	 S (=self) The patient’s own personal account or description of 
a particular experience, occurrence, or set of circumstances is 
required.
•	 O (=other) The examiner’s observation of a particular occur-
rence or set of circumstances is required or deemed appropri-
ate and sufficient.
•	 SO (=self or other)
Both types of data source should be taken into consideration 
for assessment, whereby a positive assessment of a particular 
experience, occurrence, or set of circumstances by one data 
source alone is deemed sufficient to positively confirm the pres-
ence of the symptom in question.
Figure 1 attempts to illustrate some examples.
One of the most notable innovations introduced by the AMDP 
working group, however, is the so-called AMDP decision tree, 
which details the sequence of steps necessary in the decision 
process for the assessment of each symptom (Figure 2).
The first level of the AMDP decision tree (accessibility) 
requires a decision to be made as to whether or not it is possible 
for a particular symptom to be reliably assessed. Symptoms for 
disorders of perception, for example, cannot be assessed where 
a patient refuses to communicate with the examiner or refuses 
to communicate in general or fails to respond adequately to 
the examiner’s prompts and questions. Such behavior, however, 
tends to be rare. More commonly observed are instances where 
a patient supplies insufficient information for reliable assessment 
of a particular symptom (the second level of the AMDP decision 
tree). At the third level of the AMDP decision tree, in cases where 
sufficient and reliable information is forthcoming and available, it 
remains for the examiner to make the final decision as to the pres-
ence or absence of a particular symptom. For a symptom to be 
assessed as not present, the requirement for a sufficient amount 
of information on which to base such assessment must be equally 
fully met. Where a symptom has been assessed as present, the 
degree of severity with which the symptom presents must then 
be rated (the fourth level of the AMDP decision tree). Only this 
graduation makes it possible to record the treatment process in a 
differentiated way (treatment evaluation).
It is important to remember that the AMDP-System is, in 
essence, an observer rating scale (as, e.g., the HAMD rating scale). 
Although the patient’s own statements are clearly indispensable 
and an explicit requirement for the assessment of most symptoms, 
the ultimate decision as to whether to assess a specific symptom 
as present or not always rests exclusively with the examiner alone. 
Figure 3 illustrates this point clearly.
A further important aspect of the AMDP-System was the 
development of syndrome scales. Not long after the publication 
of the AMDP Manual, first studies were conducted into devis-
ing syndrome or rating scales based on the AMDP-System pool 
of symptoms (10). Syndrome scales (observer rating scales) 
do not provide any diagnoses. They allow the quantification of 
the severity of a certain syndrome (e.g., depressive syndrome). 
The currently valid syndromes based on the AMDP-System are 
represented in Figure 4 and Table 2 below (11).
These AMDP Syndrome Scales contain a further spectrum 
of clinically relevant syndromes (e.g., depressive syndrome, 
paranoid-hallucinatory syndrome) and have been validated in 
a large number of studies and applied in numerous research 
projects, mostly in the field of psychopharmacology (12).
CliNiCAl TRAiNiNG
Training in psychopathology, despite being of primary impor-
tance, remains often patchy, unsystematic, and unstructured (13). 
Although psychopathology regularly features as a prescribed, 
compulsory staple in all psychiatric–psychotherapeutic cur-
ricula, compared with the quality of training offered in other 
psychotherapeutic areas of therapy, it remains a subject treated 
as of secondary importance only and pushed to the margins. 
While both ICD and DSM have now operationalized psychiatric 
disorders by means of strict and clearly defined diagnostic cri-
teria, they fail to define the psychopathological terminology on 
which these operationalization criteria are based. Clearly, there is 
a general unstated assumption that the user of these classification 
tools is thoroughly familiar with psychopathological terminol-
ogy and fully capable of correctly defining, for example, the term 
delusional perception  –  a symptom which, to this day, remains 
core to a diagnosis for schizophrenia (Table 1).
The AMDP-System with its lists of 100 psychopathologi-
cal, 40 somatic, and 14 optionally applicable symptoms and 
1. Accessibility 
2. Certainity 
3. Presence 
4. Severity 
Symptoms 
present 
accessible not  accessible 
questionable 
not present 
severe moderate mild 
certain 
not 
ascertained 
FiGURe 2 | The Association for Methodology and Documentation in Psychiatry (AMDP) decision tree.
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their respective definitions offers an extremely broad (albeit 
not entirely concise) range of options to describe abnormal 
behavior and experience in a patient. The advantages to be 
gained from such a stock of symptoms and their definitions 
are manifold.
 – Specific terms cannot be randomly defined and applied, since 
their definition is clearly stated in the manual. Each application 
of a specific term must be plausibly justifiable with reference to 
the definition provided for it.
 – All 140 symptoms must be assessed. This ensures the recording 
also of symptoms which may not be spontaneously reported by 
the patient, and the decision as to which symptoms to enquire 
about and which to leave out during examination is not left 
to the sole discretion of the individual examiner. This further 
enables also clear statements to be made about symptoms 
assessed as not present. The recording on the AMDP-System 
documentation form of a particular symptom as “not ascer-
tained” automatically indicates a mandatory requirement for 
further examination at a later stage, thus preempting the risk 
of individual symptoms being inadvertently overlooked dur-
ing initial examination.
 – An interview guide (14) is available for working with the 
AMDP-System. However, instead of a standardized format, 
the assessment procedure follows a semi-structured approach 
in which all symptoms must be explored as to whether they 
were experienced (S) or observed (O), to arrive at a judgment. 
The order in which the questions are asked may be freely 
chosen and their contents adapted to the requirements of the 
interview situation.
The following concrete example illustrates the potential for 
information gaps in psychopathological descriptions in cases 
where the focus remains directed at primary symptoms only (an 
extract from findings on admission for a female patient):
Awake, fully conscious. Fully orientated. Reduced atten-
tion span and poor memory. Retarded thinking. Suffers 
from the delusion of being persecuted. Experiences 
verbal hallucinations. Suspected visceral or visual 
FiGURe 4 | Development of the Association for Methodology and Documentation in Psychiatry (AMDP) syndromes.
observation by 
interviewer
self-observation by 
patient
statements by 
patient
rating by interviewer
rating of AMDP symptoms according
to the decision tree
FiGURe 3 | Pathway to decision within the Association for 
Methodology and Documentation in Psychiatry (AMDP) System.
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hallucinations, although patient denies experiencing 
these. The patient experiences emotional despair and 
markedly reduced drive. The patient reports sporadic 
experience of suicidal thoughts from which she is, 
however, able to credibly distance herself during 
examination.
On recording these details on the AMDP-System documenta-
tion form for psychopathological findings (which lists 100 symp-
toms), statements corresponding to only 19 of the symptoms 
listed in the AMDP-System are found. As regards the remaining 
81 of these symptoms, the fact whether the lack of mention of 
them in this set of findings is due to the symptoms having been 
assessed as not present, or due to not having been assessed at 
all, remains entirely open to speculation. Unfortunately, the latter 
generally tends to be the case.
In recent years, the AMDP-System has been increasingly 
deployed as an instrument in the training of practitioners in 
assessing and recording psychopathological findings. Almost all 
German text books on the subject are based on the symptoms and 
the definitions contained in the Manual, an invaluable compen-
dium which has also found its way into texts and commentaries 
on projects relating to national planning policy on public health 
and well-being and health infrastructure.
Training in the assessment and documentation of psychopath-
ological findings lends itself particularly well to group practice 
sessions. Over 30 years’ experience of regularly organized AMDP 
training seminars has been accumulated to date (13). Current 
seminars normally take place in groups of around 20 partici-
pants and are led by 2 AMDP-System-trained and -experienced 
presenters. By means of live or video-recorded examination 
interviews conducted by the presenters with three different 
patients, three case studies with three different symptomatologies 
are introduced which then each form the subject of subsequent 
in-depth discussions. After each examination interview, seminar 
participants are challenged to rate all identified symptoms based 
on the corresponding AMDP-System documentation form. This 
is then followed by a guided debate on what at this stage usually 
amounts to symptom ratings of considerable variance among 
individual participants. Each participant is required to substanti-
ate the rating of a particular symptom with examples of actual 
observed patient utterances or behavior, or with other observa-
tions made during interview. Participants are asked to adhere 
rigorously to the definitions contained in the AMDP Manual, to 
differentiate strictly between factual symptom observation and 
symptom interpretation and to resist the temptation to engage 
in any form of diagnostic assessment at this stage. It has been 
possible to show that within the course of just a single seminar, 
interrater-reliability is noticeably improved and participants’ 
TABle 2 | Association for Methodology and Documentation in Psychiatry 
(AMDP) syndromes (11).
AMDP syndromes example: manic syndrome (MANi)
•	 Paranoid-hallucinatory syndrome
•	 Depressive syndrome
•	 Psychoorganic syndrome
•	 Manic syndrome
•	 Hostility syndrome
•	 Autonomic syndrome
•	 Apathy syndrome
•	 Obsessive–compulsive syndrome
•	 Neurological syndrome
22. Flight of ideas
66. Euphoria
72. Exaggerated self-esteem
82. Increased drive
83. Motor restlessness
88. Logorrhea
93. Excessive social contact
7
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knowledge base of psychopathological terminology demonstra-
bly enhanced (15–17). It is imperative for such group coaching 
in psychopathology to occur at regular intervals. As a rule, such 
sessions are easily integrated in in-house training programs at 
individual clinics (case conferences). Only in this way can the 
continued validity and effectiveness of the AMDP-System termi-
nology be safeguarded and maintained.
The AMDP-System recording form for psychopathological 
findings, on which individual symptoms are rated, must be 
regarded as an essential, yet not wholly self-sufficient assessment 
tool. The AMDP-System operates on the premise that its purpose 
is not to act as a substitute for the freely formulated assessment 
report on psychopathological findings. Ultimately, it is this report 
which conveys an authentic picture of the assessed patient as a 
person. The value of the completed AMDP-System documenta-
tion form, however, lies in serving as an excellent basis from 
which to draw for the formulation of clinical findings and for the 
structuring of case discussions.
Intermittent critics have voiced their concern that the applica-
tion of a standardized system of the type advocated here curtails 
too strictly the flexibility and adaptability necessary to accurately 
document human experience and behavior. Such concerns are 
justified, albeit in the case of the AMDP-System somewhat 
misguided. The AMDP-System is far from claiming to be a 
comprehensive authority in the recording of all human experi-
ence and behavior. Yet, it offers a stock of clear and accessible 
terminology to draw from, in order to facilitate the compilation of 
such records and reports. By way of analogy, the AMDP-System 
may be likened to an essentially lifeless string instrument, which 
must first be mechanically tuned and intonation techniques be 
mastered before it allows for an inexhaustible range of original 
musical tunes to be successfully elicited from it. In other words, 
where psychopathological terms and definitions are unclearly 
formulated and inappropriately used (analogically speaking, a 
badly tuned string instrument played with poor intonation), the 
contents of a report on psychopathological findings (analogous 
to the musical tunes) cannot be rendered lively and precise in the 
best of circumstances.
Another point of criticism occasionally leveled against the 
AMDP-System is the length of time required to assess and rate the 
100 psychopathological symptoms listed. With sufficient practice, 
this process should, as a general rule, take up no more than 45 min. 
It must be remembered, however, that such assessment procedure 
is never limited to the recording of psychopathological findings 
alone but always simultaneously marks either the beginning or 
an intensification of a therapeutic relationship between examiner 
and patient. Patients are appreciative of sincere enquiries about 
their needs and expectations as well as their medical history 
and personal well-being. Such enquiries must be conducted in 
a sensitive and respectful manner, and in essence, they amount 
to what patients ultimately expect from their psychologists and 
psychiatrists by way of standard good practice.
Diametrically opposed to the above point of criticism is the 
objection to the fact that the AMDP-System contains a mere 100 
symptoms, which some rate as wholly inadequate to properly 
reflect the varied and multifaceted nature of human experience. 
This objection is entirely warranted, and it is by no means the 
intention of the AMDP-System to limit examiners to these 100 
symptoms, prohibiting them from going beyond that figure and 
documenting further symptoms in addition to them. Reality, 
however, appears to indicate a tendency among examiners toward 
the opposite, as was exemplified by the extract from a set of psy-
chopathological findings on admission reproduced earlier in this 
text. Practical experience shows that the number of symptoms 
being examined for tends more likely to be insufficient rather 
than adequate or even excessive.
A final and, to some extent, anachronistic charge levied 
against the AMDP-System arises from questioning the need for 
the differentiated documentation of psychopathological findings 
[for general discussion, see Ref. (18–22)]. Ultimately, so the 
argument goes, most clinical pictures are, as characteristically 
reoccurring patterns of particular disorders, easily recogniz-
able at practically first sight. It was exactly this blind belief in 
the reliability of “pattern recognition,” however, which led to 
the introduction of operationalized diagnostic criteria, since the 
perceived validity of that method was ultimately revealed as a 
myth. Attempts at developing neurobiological methods as reli-
able diagnostic markers have so far proved equally unsuccessful. 
Quite the contrary: clearly, neurobiological research is heavily 
reliant on the most precise phenotype descriptions possible in 
order to be able to create a homogeneous sample in the first place. 
Diagnostic assessments and decisions on therapies have always 
been based on psychopathological findings and will continue 
to be so for the foreseeable future. Against this background, 
unclear terminology can never result in a clear diagnosis. A case 
in point is “delusional perception.” The term “delusional percep-
tion” (Table 1) was described by Kurt Schneider (with reference 
to Jaspers and Gruhle) as a primary symptom for the diagnosis 
of schizophrenia. According to ICD-10 coding algorithms, this 
symptom continues to this day to be of enormous importance in 
diagnosing schizophrenia. What exactly, however, is “delusional 
perception”? ICD-10 contains no descriptive details for the term. 
Textbooks frequently explain instances of “delusional perception” 
in terms of true perceptions to which false, delusional meanings 
are attributed. What remains also often ignored or forgotten is 
Kurt Schneider’s caveat that for “delusional perception” to be 
diagnosed accurately, such attachment of delusional meaning 
to an otherwise accurate perception must occur without ration-
ally or emotionally justifiable underlying cause. Delusional or 
delusion-like misinterpretations of true perceptions are also 
frequently present in the absence of a schizophrenic disorder, e.g., 
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during episodes of severe depression accompanied by psychotic 
symptoms in the context of experiencing intense feelings of guilt; 
with social phobia against the background of intense feelings 
of shame; and with paranoid personality disorder as a result of 
extreme distrust (suspiciousness). In all these cases, an emotional 
trigger for misinterpretation is indicated, and yet, none is rep-
resentative of an authentic case of “delusional perception.” Only 
with an exact awareness of how “delusional perception” is defined, 
and after precise and thorough analysis as to whether an observed 
phenomenon accurately corresponds with this definition or not, 
does a valid diagnosis become possible.
Descriptive psychopathology is a sub-category of general 
psychopathology. Psychopathology as a science is not merely 
concerned with the exact description of unusual experiences 
and behavior but addresses a considerably wider range of aspects 
(hermeneutic, biographical, etc.). Without precise descriptive 
psychopathology, however, all psychiatric findings (and the 
conclusions and decisions based on them) remain arbitrary and 
ambiguous. Against this background, the AMDP-System with 
its terminology based on classic psychopathology makes an 
important contribution to education and training in the field of 
psychopathology. By continuously reiterating to the user the need 
to differentiate between carefully observed and described phe-
nomena on the one hand and their interpretation as symptoms on 
the other, it forestalls hasty decision-making and circular reason-
ing. Only in this way can an initial diagnosis be reviewed and, 
where appropriate, alternative hypotheses developed. Diagnostic 
sub-groups can be identified which, in turn, opens up opportu-
nities to investigate these homogeneous sub-groups with other 
(e.g., neurobiological) methods in the context of further research. 
A disregard for precise psychopathological description, however, 
leads any neurobiological research to failure, since such research 
will lack connection to clinical reality and become self-referential. 
First warning bells to this effect began to be sounded as far back 
as the 1990s [“Cassandra’s complaints” (21)].
“Fortunately, the Europeans still have a proud tradition 
of clinical research and descriptive psychopathology. 
Someday, in the 21st century, after the human genome 
and the human brain have been mapped, someone 
may need to organize a reverse Marshall plan so that 
the Europeans can save American science by helping 
us figure out who really has schizophrenia or what 
schizophrenia really is (23), p. 1407.
We need to make a serious investment in training 
a new generation of real experts in the science and art 
of psychopathology. Otherwise, we high-tech scientists 
may wake up in 10 years and discover that we face a 
silent spring. Applying technology without the com-
panionship of wise clinicians with specific expertise in 
psychopathology will be a lonely, sterile, and perhaps 
fruitless enterprise [(24), p. 1639].”
As is common knowledge, Troy fell and Cassandra’s prophetic 
cries went unheeded. Yet, just as Virgil once, in his Aeneid, 
picked up the thread of Homer’s Iliad anew, so there is today a 
fresh, powerful drive underway which seeks to defend and afford 
psychopathology anew its ever relevant and irrefutably proper 
place in the fields of psychiatry and clinical psychology as the 
essentially fundamental and indispensable science that it indis-
putably represents (22, 25).
THe AMDP-SYSTeM AND iTS 
APPliCATiON iN ReSeARCH AND 
CliNiCAl ROUTiNe
evaluation of the AMDP-System As an 
Assessment Tool
The publication of the AMDP-System enabled fundamental 
methodological critique in psychiatry to be performed for the 
first time. It became possible to examine the psychopathologi-
cal terms defined in the AMDP-System based on psychometric 
criteria. In essence, the primary purpose of these investigations 
was to determine whether the fairly complex psychopathological 
phenomena emanating from traditional psychiatry allowed for 
assessment in such a way that different raters arrived at concur-
ring results regarding the psychopathological state of a given 
patient. Were they to fail in this, the attempt to devise assessment 
scales for symptoms of a high degree of complexity would have to 
be abandoned. A further objective of the evaluation process was 
to examine the relation of the AMDP-System to other assessment 
procedures (especially other observer rating scales such as the 
IMPS and CPRS). In the field of psychology, with the applica-
tion of psychological testing procedures, strategies of this kind 
had long become the established norm. In psychopathology, by 
contrast, investigating for objectivity, reliability, and validity was 
uncharted territory.
In the context of reliability studies, the question of interrater-
reliability was of primary concern (26, 27). During the years when 
the AMDP-System was being developed and published, ensuring 
reliability and comparability of psychopathological findings 
and diagnoses was core. With regard to the validity of AMDP-
System-based findings, especially questions on convergent and 
divergent validity were examined. An example of this was the 
comparison of the AMDP-System Syndrome Scale for “depres-
sive syndrome” with the Bech-Rafaelsen Melancholia Scale and 
the Beck Depression Inventory (28). Only moderate correlation 
was found between observer-rating scales and self-rating scales. 
Results of investigations into the psychometric properties of the 
instrument, including factor analyses and the classification of 
findings in the tradition of psychiatry, are summarized in Berner 
(29), Pietzcker et al. (11), Baumann et al. (10), and Heimann and 
Rein (26).
The AMDP-System As an Assessment Tool 
for Methodological Questions
After extensive and thorough evaluation, the AMDP-System 
began to be applied in the examination of various methodological 
issues. Thus, the AMDP-System has always also served as a tool 
for external validation of other instruments (9). Previous teams 
of authors compared various approaches to the development of 
assessment scales from different countries. Short specialist scales 
TABle 3 | Selection of pharmacological interventions and clinical studies 
referring to schizophrenia, bipolar, and depressive disorders by use 
of the Association for Methodology and Documentation in Psychiatry 
(AMDP) System.
Study type Reference
Psychopharmacological interventions
Validity of the AMDP-System for its use in clinical 
psychopharmacology
Angst and 
Woggon (12)
Effect of neuroleptics on positive and negative symptoms and 
the deficit state
Angst et al. (35)
Pilot study of PK 11195, a selective ligand for the peripheral-
type benzodiazepine-binding sites in patients with anxious or 
depressive symptomatology
Ansseau et al. 
(37)
The tolerability and efficacy of the atypical neuroleptic 
remoxipride compared with clozapine and haloperidol in acute 
schizophrenia
Klieser et al. 
(36)
Initial triple therapy of acute mania, adding lithium and 
valproate to neuroleptics
Reischies et al. 
(38)
Clinical studies
Schizophrenia
Prevalence of alcohol and drug abuse in schizophrenic 
inpatients
Soyka et al. 
(43)
Cannabis and schizophrenia: results of a follow-up study Caspari et al. 
(44)
Insight dimensions and cognitive function in psychosis: a 
longitudinal study
Cuesta et al. 
(45)
The differentiation between “lack of insight” and “dysfunctional 
health beliefs” in schizophrenia
Linden and 
Godemann (46)
Social disability in schizophrenic, schizoaffective, and affective 
disorders
Bottlender et al. 
(47)
Long-term term outcome of schizoaffective disorder. Are there 
any differences with respect to schizophrenia?
Pinna et al. (48)
Bipolar disorder
Hallucinations in bipolar disorder: characteristics and 
comparison to unipolar depression and schizophrenia
Baethge et al. 
(49)
Prevalence of delusional jealousy in psychiatric disorders Soyka and 
Schmidt (50)
Depression
The importance of psychosocial factors, gender, and severity 
of depression in distinguishing between adjustment and 
depressive disorders
Barnow et al. 
(51)
Typus melancholicus personality structure and the 
characteristics of major depressive episode
Stanghellini 
et al. (52)
AMDP profiles predict later risk for criminal behavior and violent 
crimes in former inpatients with affective disorder
Soyka and 
Zingg (53)
The validity of self-rated psychotic symptoms in depressed 
inpatients
Seemüller et al. 
(54)
Depression with psychotic features is influenced by 
polymorphism of the serotonin transporter gene
Stamm et al. 
(55)
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[e.g., the HAMD, the BPRS, and the Clinical Global Impressions 
(CGI), etc.] were discussed in comparison with the AMDP-
System, which is representative for a comprehensive, multifaceted 
global scale. In this context, in their exemplary study, Theodoridou 
et al. (30) investigated the concurrent validity and sensitivity to 
change of the 12-item Health of Nation Outcome Scales and the 
3-item CGI in relation to the 100-item AMDP-System, which the 
authors used as a psychopathological reference scale. The cor-
relations between the instruments were significant and plausible.
Further investigations centered around the frequency and 
specificity of psychopathological symptoms, the grouping of 
symptoms into syndromes (see above), and the classification of 
the latter into specialist nosological concepts (11, 29). A com-
parison of data from various sources led to a careful differentia-
tion between self-rating and observer-rating procedures in the 
psychopathological examination process.
More recent studies focused on the empirical structure of psy-
chopathological findings and comparisons between dimensional 
and categorical diagnostic concepts in the application of AMDP 
data (31–33). In many instances, these studies relied on the 
method of multidimensional scaling for their enquiries and were 
able to fall back on earlier factor-analytic approaches. Cuesta and 
Peralta (34) investigated 660 patients suffering from an acute psy-
chotic episode and found a 10-dimensional model by principal 
component analysis including 67 items of the AMDP-System. The 
comparison of this factor solution with current psychopathologi-
cal AMDP data (31), carried out on a large random sample with 
multidimensional scaling in two-dimensional symptom cards, 
yielded clusters which were largely identical with the symptom 
areas resulting from earlier factor-analytic evaluations. Although 
some of the symptom clusters described at the time amounted 
to projections only which were neither formally confirmed nor 
established, the consistency of psychopathological symptom 
structures found over a period of some 20  years remained 
impressive.
The AMDP-System As an evaluation Tool 
for Clinical Proof of Concept
Given the underlying objectives guiding the development of 
the AMDP-System as an instrument for the documentation 
and assessment of the effectiveness of psychopharmacological 
intervention, clinical-pharmacological studies play an important 
role (12, 15). Studies on the effectiveness of antidepressants and 
antipsychotics are now widely available (35, 36), and the effective-
ness of benzodiazepines was investigated by Ansseau et al. (37).
Reischies et al. (38) discussed the combined treatment of acute 
mania. The relevance of the AMDP-System “Apathy Syndrome” 
scale in the measuring of the effectiveness of intervention was 
investigated by Reischies and Stieglitz (39). Occasionally, somatic 
findings contained in the AMDP-System are applied separately 
in order to document the side effects of pharmacotherapy [e.g., 
Ref. (40, 41)].
Volz et al. (42) chose as their subject of investigation the effects 
of various forms of light therapy on the symptoms of depressed 
patients.
The AMDP-System in Clinical Studies
On account of its broad range of descriptions of psychopathologi-
cal phenomena, the AMDP-System is encountered in many clini-
cal studies in the context of a range of distinctly diverse issues, as 
the following paragraphs illustrate (Table 3). Given the relatively 
concentrated focus on schizophrenic and affective disorders 
during the development of the AMDP-System, most available 
studies center around aspects of these two disorders. Based on 
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the example of schizophrenic disorders, Cuesta and Peralta (34) 
demonstrated the need to combine neurobiological studies with 
differentiated psychopathological assessment instruments such 
as the AMDP-System.
Caspari (44) investigated the relationship between schizo-
phrenia and cannabis consumption, while Soyka et  al. (43) 
looked into alcohol and drug abuse among patients with schizo-
phrenia. Frequency levels of hallucinations co-occurring with 
schizophrenia, bipolar disorder, and unipolar depression formed 
the subject of enquiry in Baethge et  al. (49). In a comparative 
longitudinal study of schizophrenic and schizoaffective patients, 
Pinna et al. (48) addressed issues surrounding the documentation 
of symptom regression and functional remission in both types 
of disorder. The effects of schizophrenic, schizoaffective, and 
affective disorders on social functionality were investigated by 
Bottlender et al. (47). Möller et al. (56) used the AMDP-System 
as an outcome criterion in their longitudinal study into schizo-
phrenic and affective disorders. A specialist psychopathological 
enquiry focused on the question of levels of lack of insight with 
schizophrenic patients (57). In their longitudinal study, Cuesta 
et  al. (45) were able to demonstrate that a patient’s cognitive 
performance had insignificant bearing on insight dimensions. 
Linden and Godemann (46) in their investigation into lack of 
insight (also assessable with the AMDP-System) and delusional 
convictions in response to enquiries addressing personal health 
and well-being with schizophrenic patients were able to present 
these issues as two distinct constructs. The relationship between 
delinquency and violence in schizophrenic patients formed the 
subject of a study which Soyka et al. (58) undertook by applying 
the AMDP-System. They found that high score values in relation 
to hostility syndrome and manic syndrome in schizophrenic and 
bipolar patients may be indicative of an increased risk of criminal 
behavior (50, 53). Delusions of jealousy is a relatively rare symp-
tom in patients suffering from schizophrenia and other psychotic 
disorders. Such patients are considerably more likely to display a 
tendency toward aggression and violence (50).
The significance of psychotic symptoms in depressed patients 
formed the subject of two further studies (54, 55), while Barnow 
et al. (51) investigated the degree of impact exercised by levels 
of severity of depressive disorders. Zahn et al. (59) enquired into 
the significance of self-blame and feelings of worthlessness in the 
context of depressive disorders. Stanghellini et al. (52) applied the 
AMDP-System in their study into typus melancholicus.
The AMDP-System has also been used in connection with 
other psychiatric disorders. Bidzan et  al. (60), for example, 
investigated the psychopathological syndrome of Alzheimer’s 
disease. Krasnianski et  al. (61) applied the AMDP-System in 
their description of prevalence rates and natural progression of 
psychopathological symptoms over time in the case of Creutzfeld-
Jakob disease. In a longitudinal study on patients suffering from 
Parkinson’s disease who had undergone subthalamic nucleus 
stimulation, Drapier et al. (62) used the AMDP-System to evalu-
ate symptoms of anxiety. The psychopathological patterns found 
in eating disorders were looked at by Speranza et al. (63).
In the context of currently evolving demographic changes in 
population structure, the work by Braca et al. (64) on the psycho-
pathology of migrants is of particular interest. In their estimation, 
the AMDP-System with its wide spectrum of psychopathology is 
of specific relevance in this context, as evidenced by Diefenbacher 
and Heim (65) study on Turkish patients (1994).
The AMDP-System in everyday Clinical 
Practice
In Germany, the AMDP-System forms the basis for the docu-
mentation of psychopathological findings and quality control 
in a number of psychiatric clinics (66) and is generally applied 
in the context of examinations on admission and discharge. 
Comparability of psychopathological findings is being ensured 
through regular attendance of training seminars by those in 
charge of documenting such findings. The AMDP-System is also 
increasingly regularly used as a module in the documentation of 
findings in electronically stored patient medical histories. Equally, 
the AMDP-System is gaining ground in the area of psychiatric 
expert testimony.
CONClUSiON AND PeRSPeCTiveS
A profound grasp of descriptive psychopathology and high levels 
of proficiency in its practical application form part of the most 
fundamental skills set of a psychiatrist or psychologist. Compared 
to training courses in psychotherapy, the minimalist approach 
adopted toward descriptive psychopathology in the design and 
delivery of training courses in psychiatry is surprising, to say 
the least, given that descriptive psychopathology represents the 
bedrock of operationalized diagnosis for psychiatric disorders 
and the planning of targeted therapy. While in the field of psycho-
therapy the general expectation of the experienced psychiatrist 
or psychologist is that they would have spent a considerable 
number of years studying psychotherapeutic procedure, initial 
psychiatric-psychological training includes a cursory introduc-
tion to descriptive psychopathology only.
Since the first beginnings of psychopharmacology over 50 years 
ago, however, the AMDP-System has been available as a compre-
hensive and continuously improved and updated observer-rating 
scale, enabling the description of a multitude of different facets 
of psychopathology. The AMDP-System has been translated into 
several major languages, and since its first publication in 1971 
it has, alongside its clinical application, been used in a growing 
number of studies. Not only does the AMDP-System facilitate the 
differentiated documentation of findings at symptom level but 
also enables a differentiated description of the most important 
psychiatric syndromes in the form of AMDP Syndrome Scales. 
The latest edition of the AMDP-System distinguishes itself from 
earlier ones by offering further precision in its descriptions as 
well as an extension of the range of symptoms described, thus 
opening up opportunities for still wider clinical application and 
new areas of research.
The development of the new edition of the DSM originally 
triggered an extremely critical international discussion about the 
notion of illness in psychiatry and the meaningfulness of a widely 
extended range of diagnoses. From this has grown widespread 
skepticism toward psychiatric classification per se. In a climate of 
such skepticism, an instrument such as the AMDP-System, which, 
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rather than being based on conceptual diagnostic categories, is 
oriented toward the fundamental phenomenology of experience 
and behavior, carries within it great potential for improvements 
in clinical practice as well as for innovation in research.
Especially in times of increasing awareness of the biological 
basis underlying psychiatric disorders and considering also the 
steadily increasing stream of new developments in imaging 
techniques and genetic procedures, there is now more than ever 
a call for a system like the AMDP-System. Against the back-
ground of such new levels of awareness and technical advances 
in diagnostic procedures, the AMDP-System, with its express 
focus on the smallest unit of psychiatric observation, i.e., the 
symptom, represents the key to a much needed and increasingly 
essential correlation of technical findings with experience and 
behavior of the patients themselves. Against this background, 
the AMDP-System coincides entirely with tendencies in 
current research such as the Research Domain Criteria (67), 
which define the differentiated and precise documentation of 
the smallest possible single phenomena as the initial target and 
the basis upon which to conduct subsequent further analyses 
of a more complex nature. The AMDP-System undoubtedly 
answers the requirements in support of this approach in full 
and thus re-affirms and cements its position as the cornerstone 
of effective and comprehensive psychopathological assessment 
as well as of training in psychiatry and clinical psychology at 
all levels.
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